US OptionsDetailed Quotes
ABBV240816P167500
- 0.05
- -0.08-61.54%
15min DelayClose Aug 12 16:00 ET
0.05High0.04Low
0.05Open0.13Pre Close200 Volume161 Open Interest167.50Strike Price977.00Turnover76.04%IV11.95%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0569Delta0.0073Gamma481.47Leverage Ratio-0.1875Theta-0.0012Rho-27.39Eff Leverage0.0237Vega
AbbVie Stock Discussion
Sign in to post a comment
$Verizon (VZ.US)$ $Cadence Design Systems (CDNS.US)$ $NXP Semiconductors (NXPI.US)$ $Coca-Cola (KO.US)$ $GE Aerospace (GE.US)$ $Spotify Technology (SPOT.US)$ $Alphabet-A (GOOGL.US)$ $Tesla (TSLA.US)$ $Visa (V.US)$ $Texas Instruments (TXN.US)$ $Vertiv Holdings (VRT.US)$ $ServiceNow (NOW.US)$ $KLA Corp (KLAC.US)$ $IBM Corp (IBM.US)$ $Chipotle Mexican Grill (CMG.US)$ $Ford Motor (F.US)$ $AbbVie (ABBV.US)$ $American Airlines (AAL.US)$ $British American Tobacco (BTI.US)$ $Bristol-Myers Squibb (BMY.US)$ $3M (MMM.US)$
📊⚡️📊
📊⚡️📊
7
1
Roughly a quarter of the companies in the S&P 500 are scheduled to release their second-quarter results this week. Investors will be particularly focused on updates from some of the 'Magnificent Seven', which will reveal whether the artificial intelligence (AI) trend continues.
$Alphabet-A (GOOGL.US)$, the parent company of Google, is expected to report revenue of $84.3bn and net income of $23bn, or $1.85 per share, in ...
$Alphabet-A (GOOGL.US)$, the parent company of Google, is expected to report revenue of $84.3bn and net income of $23bn, or $1.85 per share, in ...
+3
102
20
$Genmab (GMAB.US)$ $AbbVie (ABBV.US)$
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
5
$Chevron (CVX.US)$
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
33
3
From YouTube
6
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co (MRK.US)$ $Bristol-Myers Squibb (BMY.US)$ $Johnson & Johnson (JNJ.US)$ $Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $AbbVie (ABBV.US)$
$Merck & Co (MRK.US)$ $Bristol-Myers Squibb (BMY.US)$ $Johnson & Johnson (JNJ.US)$ $Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $AbbVie (ABBV.US)$
10
1
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie (ABBV.US)$ +189%
$Bristol-Myers Squibb (BMY.US)$ +175%
$Johnson & Johnson (JNJ.US)$ +95%
$AstraZeneca (AZN.US)$ +78%
$NVM +45%
$Merck & Co (MRK.US)$ +37%
$ROCHE HOLDING AG (RHHBY.US)$ +27%
$Pfizer (PFE.US)$ +13%
$GlaxoSmithKline (GSK.US)$ +13%
----- $SPDR S&P 500 ETF (SPY.US)$ +12% -----
$Sanofi (SNY.US)$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie (ABBV.US)$ +189%
$Bristol-Myers Squibb (BMY.US)$ +175%
$Johnson & Johnson (JNJ.US)$ +95%
$AstraZeneca (AZN.US)$ +78%
$NVM +45%
$Merck & Co (MRK.US)$ +37%
$ROCHE HOLDING AG (RHHBY.US)$ +27%
$Pfizer (PFE.US)$ +13%
$GlaxoSmithKline (GSK.US)$ +13%
----- $SPDR S&P 500 ETF (SPY.US)$ +12% -----
$Sanofi (SNY.US)$ +3%
Source: Arjun Murthy on the HR app!
7
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
30
37
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
10baggerbamm : big day Wednesday hopefully we see I knock the cover off the ball moment exceed whisper number exceed revenue number and exceed forward guidance expectations if we can achieve that it's over 100 bucks